Skip to main content
FEMY logo

FEMY · Femasys Inc · Documents

Track FEMY — free
$1.12 -0.16 (-12.50%) At close · Nov 17
Market Cap
$9.70M
Shares
8.66M
Volume · Nov 17 110.56K Avg daily vol (3M) 695.5K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $2.29M up 40.8% 10-K filed Mar 31, 2026 Quarterly report New FY2026 Q3 Revenue $404.6K down 44.5% 10-Q filed Nov 13, 2026 Latest results New Private placement funds commercial expansion despite sales decline 8-K filed Nov 13, 2026
2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Sales fall 21.5% as nine-month net loss narrows

Femasys reported nine-month sales of $1,161,313, down 21.5%, and a net loss of $8,187,810, narrowed from $14,677,582. Cash and cash equivalents stood at $23,913,946 as of September 30, 2026.

Revenue $404.6K ▼ 44.5% Net loss $4.56M Diluted EPS -$0.53
Read from the MD&A section
3 source passages
Sales | 1,161,313 | | 1,479,926 | | (318,613) | | (21.5)% Net loss | (8,187,810) | | (14,677,582) | | 6,489,772 | | (44.2)% As of September 30, 2026, we had $23,913,946 of cash and cash equivalents and an accumulated deficit of $154,013,954. Open the document at this passage
Nov 13
Current report 8-K
Private placement funds commercial expansion despite sales decline

Femasys completed a $30 million private placement to fund U.S. commercial expansion; overall sales fell 44.5% to $404,597, net loss was $4,564,815, and cash was approximately $23.9 million as of September 30, 2026.

Financial results
4 source passages
Completed $30 million private placement with potential total proceeds of up to $85 million upon full cash exercise of warrants, to build-out the U.S. commercial team needed to support revenue growth following recent availability of the FemaSeed^®^ fertility portfolio to OB/GYNs, and to fund the FemBloc^®^ pivotal trial to support U.S. approval. Sales in the U.S.<br>increased slightly to $347,039 in 2026 from $336,594 in 2025, while overall sales decreased by $324,797, or 44.5%, to $404,597 from $729,394. Net loss was $4,564,815, or ($0.53) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2026, compared to a net loss of $4,194,821, or ($2.05) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2025. Cash and cash equivalents as of September 30, 2026, were approximately $23.9 million and the Company had an accumulated deficit of approximately $154.0 million. Open the document at this passage
Nov 2
Current report 8-K Events of Oct 30
John Moorhead joins board as independent Class II director

Femasys Inc. appointed John Moorhead as an independent Class II director on October 30, 2026; Kenneth D. Eichenbaum also resigned as a director that day without dispute.

Director or officer change, or executive pay, Regulation FD disclosure
3 source passages
On October 30, 2026, Kenneth D. Eichenbaum, M.D., M.S.E., informed the Board of Directors (the “Board”) of Femasys Inc. (the “Company”) of his resignation as a director of the Company, effective as of that date. On October 30, 2026, the Board appointed John Moorhead as a director of the Company, effective as of that date. Mr. Moorhead will hold office as a Class II director for a term expiring at the 2029 annual meeting, at which time he will stand for election by the stockholders of the Company. The Board determined that Mr. Moorhead is an independent director for purposes of the Nasdaq listing requirements and will serve as a member of the Audit Committee and Compensation Committee of the Company. Open the document at this passage
Aug 14
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $331.83K ▼ 18.9% Net loss $4.47M Diluted EPS -$1.33
Jun 24
Current report 8-K Events of Jun 23
Other events AI summary on its way
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $424.89K ▲ 24.5% Net income $846.1K Diluted EPS $0.00
Apr 30
Proxy statement DEF 14A Meeting Jun 24, 2026
Proxy statement AI summary on its way
Apr 6
Proxy statement DEF 14A Meeting Apr 29, 2026
Proxy statement AI summary on its way
Mar 31
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $2.29M ▲ 40.8% Net loss $18.63M Diluted EPS -$0.47
Mar 27
Proxy statement PRE 14A Meeting Apr 29, 2026
Proxy statement AI summary on its way
2025
Showing 1–50 of 155 documents
Key facts CIK 1339005 CUSIP 31447E204 13F (30d) 26 filings 26 filers Visit website Investor relations